These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 8322492)

  • 1. Recombinant-expressed virus-like particle pseudotypes as an approach to vaccine development.
    McGuigan LC; Stallard V; Roos JM; Payne LG
    Vaccine; 1993; 11(6):675-8. PubMed ID: 8322492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV.
    Ourmanov I; Brown CR; Moss B; Carroll M; Wyatt L; Pletneva L; Goldstein S; Venzon D; Hirsch VM
    J Virol; 2000 Mar; 74(6):2740-51. PubMed ID: 10684290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination.
    Barouch DH; Santra S; Kuroda MJ; Schmitz JE; Plishka R; Buckler-White A; Gaitan AE; Zin R; Nam JH; Wyatt LS; Lifton MA; Nickerson CE; Moss B; Montefiori DC; Hirsch VM; Letvin NL
    J Virol; 2001 Jun; 75(11):5151-8. PubMed ID: 11333896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced cellular immune responses to SIV Gag by immunization with influenza and vaccinia virus recombinants.
    Nakaya Y; Zheng H; García-Sastre A
    Vaccine; 2003 May; 21(17-18):2097-106. PubMed ID: 12706700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.
    Ourmanov I; Bilska M; Hirsch VM; Montefiori DC
    J Virol; 2000 Mar; 74(6):2960-5. PubMed ID: 10684319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of positive cellular and humoral immune responses by a prime-boost vaccine encoded with simian immunodeficiency virus gag/pol.
    Someya K; Ami Y; Nakasone T; Izumi Y; Matsuo K; Horibata S; Xin KQ; Yamamoto H; Okuda K; Yamamoto N; Honda M
    J Immunol; 2006 Feb; 176(3):1784-95. PubMed ID: 16424209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in the B and T cell immune response to the envelope glycoprotein 130 (gp130) of the macaque strain of simian immunodeficiency virus (SIVmac), induced by immunization of rhesus macaques with virus-derived or vaccinia virus-expressed gp130.
    Voss G; Dittmer U; Coulibaly C; Makoschey B; Petry H; Lüke W; Hunsmann G
    J Gen Virol; 1993 Sep; 74 ( Pt 9)():1757-63. PubMed ID: 8376957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the expression and immunogenicity of poliovirus replicons that encode simian immunodeficiency virus SIVmac239 Gag or envelope SU proteins.
    Anderson MJ; Porter DC; Moldoveanu Z; Fletcher TM; McPherson S; Morrow CD
    AIDS Res Hum Retroviruses; 1997 Jan; 13(1):53-62. PubMed ID: 8989427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins.
    Leung NJ; Aldovini A; Young R; Jarvis MA; Smith JM; Meyer D; Anderson DE; Carlos MP; Gardner MB; Torres JV
    Virology; 2000 Mar; 268(1):94-103. PubMed ID: 10683331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo induction of cellular and humoral immune responses by hybrid DNA vectors encoding simian/human immunodeficiency virus/hepatitis B surface antigen virus particles in BALB/c and HLA-A2-transgenic mice.
    Marsac D; Puaux AL; Rivière Y; Michel ML
    Immunobiology; 2005; 210(5):305-19. PubMed ID: 16164038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of immune responses to SIV antigens by mucosally administered vaccines.
    Moldoveanu Z; Vzorov AN; Huang WQ; Mestecky J; Compans RW
    AIDS Res Hum Retroviruses; 1999 Nov; 15(16):1469-76. PubMed ID: 10555110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus.
    Murphy CG; Lucas WT; Means RE; Czajak S; Hale CL; Lifson JD; Kaur A; Johnson RP; Knipe DM; Desrosiers RC
    J Virol; 2000 Sep; 74(17):7745-54. PubMed ID: 10933680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
    J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herpes simplex virus type 1-vaccinia virus recombinant expressing glycoprotein B: protection from acute and latent infection.
    Willey DE; Cantin EM; Hill LR; Moss B; Notkins AL; Openshaw H
    J Infect Dis; 1988 Dec; 158(6):1382-6. PubMed ID: 2848904
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunogenicity of recombinant vaccinia viruses that display the HIV type 1 envelope glycoprotein on the surface of infectious virions.
    Katz E; Moss B
    AIDS Res Hum Retroviruses; 1997 Nov; 13(17):1497-500. PubMed ID: 9390748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of the parental virus strain on the virulence and immunogenicity of recombinant vaccinia viruses expressing HBV preS2-S protein or VZV glycoprotein I.
    Kutinová L; Ludvíková V; Krystofová J; Otavová M; Simonová V; Nĕmecková S; Hainz P; Vonka V
    Vaccine; 1996 Aug; 14(11):1045-52. PubMed ID: 8879101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of lentivirus-like particles alone and in combination with live vaccinia-virus-based vaccines.
    Panicali DL; Mazzara G; Sullivan JL; Hesselton R; Shen L; Letvin N; Daniel M; Desrosiers R; Stott EJ
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1449. PubMed ID: 1466979
    [No Abstract]   [Full Text] [Related]  

  • 18. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
    Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation and evaluation of a recombinant modified vaccinia virus Ankara vaccine for rabies.
    Weyer J; Rupprecht CE; Mans J; Viljoen GJ; Nel LH
    Vaccine; 2007 May; 25(21):4213-22. PubMed ID: 17434244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.
    Pal R; Venzon D; Letvin NL; Santra S; Montefiori DC; Miller NR; Tryniszewska E; Lewis MG; VanCott TC; Hirsch V; Woodward R; Gibson A; Grace M; Dobratz E; Markham PD; Hel Z; Nacsa J; Klein M; Tartaglia J; Franchini G
    J Virol; 2002 Jan; 76(1):292-302. PubMed ID: 11739694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.